Natural Alternatives International: Fiscal 2017 Q1 Results

Natural Alternatives International hat den Gewinn im ersten Quartal des neuen Geschäftsjahres 2017 Zahlen verdoppelt. Wir veröffentlichen die Mitteilung des Nahrungsergänzungsmittelherstellers aus Kalifornien dazu im Wortlaut.

Die untenstehende Meldung ist eine Original-Meldung des Unternehmens. Sie ist nicht von der bearbeitet. Die presserechtliche Verantwortlichkeit liegt bei dem meldenden Unternehmen.

CARLSBAD, California - Natural Alternatives International, Inc. ("NAI") (NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, announced net income of $2.5 million, or $0.37 per diluted share, on net sales of $34.1 million for the quarter ended September 30, 2016.

Net sales during the three months ended September 30, 2016 increased $12.5 million, or 57.8%, from $21.6 million recorded in the comparable prior year period.  For the quarter ended September 30, 2016, private label contract manufacturing sales increased $11.1 million, or 68.3%, from the comparable quarter last year.  Our first quarter fiscal 2017 contract manufacturing sales were favorably impacted due to timing and shipment of orders and new product launches. On an annualized basis we expect our fiscal 2017 revenue growth percentage to be approximately 20% to 30%. CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue increased 25.7% to $6.7 million during the first quarter of fiscal 2017 as compared to $5.3 million for the first quarter of fiscal 2016.  The increase in CarnoSyn® beta-alanine revenue was primarily due to the addition of new customers and increased material shipments to existing customers.

Net income for our first quarter of fiscal 2017 was $2.5 million, or $0.37 per diluted share, compared to net income of $1.2 million, or $0.18 per diluted share, in the first quarter of fiscal 2016. This increase was primarily attributable to increased sales and improved operational throughput with lower per unit manufacturing costs related to our private label contract manufacturing segment and increased product margin from CarnoSyn® beta-alanine sales due to increased sales and lower supply chain costs, partially offset by increased legal costs associated with our efforts to enforce compliance with our patents related to instant release CarnoSyn® and to protect our trade name in the market place against parties who are using it without our consent.

As of September 30, 2016, NAI had cash of $17.8 million and working capital of $37.8 million compared to $19.7 million and $36.7 million, respectively, as of June 30, 2016.  As of September 30, 2016, we had $10.5 million available under our line of credit agreements.

Mark A. Le Doux, Chairman and Chief Executive Officer stated, "Our first fiscal quarter was outstanding on a year over year comparative basis, both revenues and profits soared for the period.

"Now that we have concluded much of our capacity enhancements in both California and Switzerland, we are focused on expanding our sales partnerships throughout the world.  We look forward to continued growth as strategic sales initiatives, new product introductions, and new product registrations allow."

NAI, headquartered in Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see our website at

Aktuell, seriös und kostenlos: Der ECOreporter-Newsletter. Seit 1999.
Nach oben scrollen
ECOreporter Journalistenpreise